Evidence and findings
The trial randomized 247 adults with nonalcoholic steatohepatitis to vitamin E, pioglitazone or placebo for ninety-six weeks. Vitamin E improved the primary histologic outcome in 43 percent versus 19 percent with placebo. [1]
Liver enzymes and some inflammatory or fat-related histology measures improved, but the fibrosis comparison was not significant. The trial’s prespecified significance threshold also mattered when interpreting its two primary comparisons. [1]
Interpretation and limits
This population does not represent every person with fatty liver, diabetes or cirrhosis. NIH grants are listed in the retrieved record; complete funding and conflict disclosures were not established from the abstract. The trial does not provide a universal self-treatment regimen. [1]
A hypothetical distinction
Imagine a composite outcome improves through several components while fibrosis does not. Calling that result fibrosis reversal would misstate the evidence.
| Detail | Interpretation |
|---|---|
| Composite improvement | Defined trial outcome |
| Fibrosis | Separate nonsignificant result |
| Other populations | Need separate evidence |

Sources for this article
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.